Phase II trial of amivantamab plus monochemotherapy in platinum unfit NSCLC patients with EGFR exon20 insertion mutations

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-520676-26-00

Enrollment

Registered

2025-09-11

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer (NSCLC)

Brief summary

Objective Response Rate (ORR) according to RECIST 1.1

Detailed description

Median PFS, Median OS, Duration of response, Safety

Interventions

DRUGJNJ-61186372

DRUGPemetrexed Ever Pharma 25 mg/ml concentrato per soluzione per infusione

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Objective Response Rate (ORR) according to RECIST 1.1	—

Secondary

Measure	Time frame
Median PFS, Median OS, Duration of response, Safety	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026